Patents by Inventor Francis P. McCormick

Francis P. McCormick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6617496
    Abstract: A strategy for effecting virus resistance in plants causes the transcription in the plant cells of negative RNA strands which are substantially complementary to a target RNA strand. The target RNA strand can be an mRNA transcript created in gene expression, a viral RNA, or other RNA present in the plant cells. The negative RNA strand is complementary to at least a portion of the target RNA strand to inhibit its activity in vivo.
    Type: Grant
    Filed: October 16, 1985
    Date of Patent: September 9, 2003
    Assignee: Monsanto Company
    Inventors: Francis P. McCormick, Kenneth A. Barton, William F. Swain
  • Patent number: 5830684
    Abstract: Native Type II GAP (GTPase activating protein), its uses in cancer diagnosis, and methods for obtaining and purifying native and recombinant Types I and II GAPs are described.
    Type: Grant
    Filed: December 7, 1990
    Date of Patent: November 3, 1998
    Assignee: Chiron Corporation
    Inventors: Robert Halenbeck, Kirston Koths, Francis P. McCormick, Bonnee Rubinfeld, Edward C. O'Rourke, Robin Clark, Gail L. Wong, George Martin
  • Patent number: 5795779
    Abstract: .beta.-interferon is produced in Chinese hamster ovary cells (CHO) in high amounts.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: August 18, 1998
    Assignees: Berlex Laboratories, Inc., Leland Stanford Junior University
    Inventors: Francis P. McCormick, Michael A. Innis, Gordon M. Ringold
  • Patent number: 5773237
    Abstract: The subject invention provides for nucleotide sequences encoding polypeptide p62 and derivatives thereof. Another aspect of the subject invention also provides for methods of purifying p62 and derivatives thereof from cells naturally producing p62 and from cells genetically modified so as to produce p62.The subject invention also provides for methods of assaying tyrosine kinase activity by means of measuring the phosphorylation of p62 and p62 derivatives. Measurement of p62/p62 derivative phosphorylation may be used to determine whether or not a call is cancerous.
    Type: Grant
    Filed: November 1, 1996
    Date of Patent: June 30, 1998
    Assignee: Chiron Corporation
    Inventors: Gail L. Wong, Francis P. McCormick
  • Patent number: 5763573
    Abstract: Peptides, that inhibit GAP stimulated ras p21 hydrolysis of GTP; peptides that mediate dissociation of GDP from ras p21-GTP complex; and antibodies to the peptides are described. These peptides are useful as cancer diagnostics and therapeutics, particularly to detect cancer cells with an over expression of normal or oncogenic ras p21 protein and to treat cancer caused by ras oncogene. Methods for assaying products of oncogenes using the described peptides and antibodies are also disclosed. Method for treating cancer caused by ras oncogenes is also disclosed.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: June 9, 1998
    Assignee: Chiron Corporation
    Inventors: Francis P. McCormick, Gail L. Wong, Paul G. Polakis, Bonnee Rubinfeld
  • Patent number: 5760203
    Abstract: Guanosine triphosphatase activating protein (GAP) DNA sequences are described that are useful as cancer diagnostics, particularly to detect cancer cells that express the ras oncogene protein p21 by measuring the level of GAP gene expression or amplification.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: June 2, 1998
    Assignee: Chiron Corporation
    Inventors: Gail L. Wong, George Martin, Francis P. McCormick, Bonnee Rubinfeld, Edward C. O'Rourke, Robin Clark
  • Patent number: 5731427
    Abstract: The subject invention provides for nucleotide sequences encoding polypeptide p62 and derivatives thereof. Another aspect of the subject invention also provides for methods of purifying p62 and derivatives thereof from cells naturally producing p62 and from cells genetically modified so as to produce p62. The subject invention also provides for methods of assaying tyrosine kinase activity by means of measuring the phosphorylation of p62 and p62 derivatives. Measurement of p62/p62 derivative phosphorylation may be used to determine whether or not a call is cancerous.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: March 24, 1998
    Assignee: Chiron Corporation
    Inventors: Gail L. Wong, Francis P. McCormick
  • Patent number: 5652130
    Abstract: A drug delivery virion which contains an expression system for the desired protein active ingredient packaged in an envelope derived from a retrovirus is especially useful in administering materials which need to cross cell membranes in order to serve their function.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: July 29, 1997
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Francis P. McCormick
  • Patent number: 5635399
    Abstract: A drug delivery virion which contains an expression system for the desired protein active ingredient packaged in an envelope derived from a retrovirus is especially useful in administering materials which need to cross cell membranes in order to serve their function.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 3, 1997
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Francis P. McCormick
  • Patent number: 5610276
    Abstract: The subject invention provides for nucleotide sequences encoding polypeptide p62 and derivatives thereof. Another aspect of the subject invention also provides for methods of purifying p62 and derivatives thereof from cells naturally producing p62 and from cells genetically modified so as to produce p62.The subject invention also provides for methods of assaying tyrosine kinase activity by means of measuring the phosphorylation of p62 and p62 derivatives. Measurement of p62/p62 derivative phosphorylation may be used to determine whether or not a call is cancerous.
    Type: Grant
    Filed: May 17, 1991
    Date of Patent: March 11, 1997
    Assignee: Chiron Corporation
    Inventors: Gail L. Wong, Francis P. McCormick
  • Patent number: 5376567
    Abstract: DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The human recombinant interferon so produced contains glycans which are a subset of the population of glycans which are contained in the native counterpart, and may be used in therapeutic formulations. The CHO cells yield high levels of human interferon with no detectable amounts of host, IFN, either constitutive or inductive.
    Type: Grant
    Filed: January 9, 1992
    Date of Patent: December 27, 1994
    Assignees: Berlex Laboratories, Inc., Board of Trustees of the Leland Stanford, Jr. Univ.
    Inventors: Francis P. McCormick, Michael A. Innis, Gordon M. Ringold
  • Patent number: 5104975
    Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.
    Type: Grant
    Filed: July 8, 1988
    Date of Patent: April 14, 1992
    Assignee: Cetus Corporation
    Inventors: Francis P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey
  • Patent number: 5057410
    Abstract: The invention provides highly sensitive methods for detecting specific sequences contained in chimeric mRNA. The mRNA sequences are reverse transcribed into complementary DNA (cDNA), amplified by the Polymerase Chain Reaction, and detected by hybridization with a labeled sequence specific oligonucleotide probe. The method is particularly valuable for the detection of chimeric mRNAs experessed by activated oncogenes that result from aberrant genetic rearragements such as chromosomal translocations.
    Type: Grant
    Filed: August 5, 1988
    Date of Patent: October 15, 1991
    Assignee: Cetus Corporation
    Inventors: Ernest S. Kawasaki, Francis P. McCormick, Owen O. Witto
  • Patent number: 4966843
    Abstract: DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The human recombinant interferon so produced contains glycans which are a subset of the population of glycans which are contained in the native counterpart, and may be used in therapeutic formulations. The CHO cells yield high levels of human interferon with no detectable amounts of host IFN, either constitutive or inductive.
    Type: Grant
    Filed: July 31, 1985
    Date of Patent: October 30, 1990
    Assignee: Cetus Corporation
    Inventors: Francis P. McCormick, Michael A. Innis, Gordon M. Ringold
  • Patent number: 4798787
    Abstract: Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipitated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: October 17, 1984
    Date of Patent: January 17, 1989
    Assignee: Cetus Corporation
    Inventors: Francis P. McCormick, Gail L. Wong, Robin Clark, Norman Arnheim, Danute E. Nitecki
  • Patent number: 4762706
    Abstract: Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipitated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: October 17, 1984
    Date of Patent: August 9, 1988
    Assignees: Cetus Corporation, Cold Spring Harbor Laboratories
    Inventors: Francis P. McCormick, Gail L. Wong, Robin Clark, Norman Arnheim, Danute E. Nitecki, James R. Feramisco
  • Patent number: RE35171
    Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.
    Type: Grant
    Filed: April 14, 1994
    Date of Patent: March 5, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Francis P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey